Compare HWBK & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HWBK | VCRE |
|---|---|---|
| Founded | 1865 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.2M | 271.7M |
| IPO Year | 1996 | 2026 |
| Metric | HWBK | VCRE |
|---|---|---|
| Price | $37.77 | $9.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $29.21 |
| AVG Volume (30 Days) | 13.9K | ★ 23.5K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ 31.42 | N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $119.57 |
| Revenue Next Year | N/A | $508.89 |
| P/E Ratio | $20.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.42 | $7.88 |
| 52 Week High | $40.60 | $13.15 |
| Indicator | HWBK | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 40.58 |
| Support Level | $37.06 | $8.79 |
| Resistance Level | $40.37 | $12.08 |
| Average True Range (ATR) | 0.84 | 0.83 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 36.48 | 28.40 |
Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, and checking, savings and money market accounts. It has two segments, banking and wealth management, with the banking segment earning the majority of its revenue and conducting general banking business, offering checking and savings accounts, internet banking, debit cards, certificates of deposit, brokerage services and others. Its primary source of revenue is net interest income derived from lending and deposit taking activities.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.